Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19.

Autor: Fazeli A; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran., Sharifi S; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran., Behdad F; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran., Okati S; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran., Esmaielifar G; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran., Jelveh N; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran., Eshghi P; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: peshghi64@gmail.com., Mohammadi S; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran; Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: smohammadi@sina.tums.ac.ir.
Jazyk: angličtina
Zdroj: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis [Transfus Apher Sci] 2022 Apr; Vol. 61 (2), pp. 103321. Date of Electronic Publication: 2021 Nov 24.
DOI: 10.1016/j.transci.2021.103321
Abstrakt: Background and Objectives: The use of COVID-19 convalescent plasma (CCP) has been approved by the FDA. We assessed the outcome of patients with moderate and severe COVID-19 following convalescent plasma therapy and the association with variables such as antibody titer in CCP units and transfusion time.
Materials and Methods: In this prospective cohort study, 3097 patients with moderate and severe COVID-19 (according to WHO Progression Scale) had heterogeneous demographic and clinical characteristics received plasma with an unknown titer at the transfusion time. Firstly, information about age, sex, blood group, the time interval from hospitalization to CCP transfusion, underlying disease, and antibody titer with the outcome were investigated. Then, multivariate logistic regression and area under the curve (AUC) were performed for the association between disease severity and intubation variables with transfusion time and outcome.
Results: Patients with younger age receiving CCP in the first five days of hospitalization had lower mortality (P < 0.0001). Moreover, patients without the underlying disease had lower mortality (P < 0.001). The mortality rate also decreased in severe patients who were intubated receiving CCP for less than five days (P < 0.001). In patients with moderate severity (score less than 5) who received IgG antibody levels above 1:320 in less than five days had lower mortality (P < 0.0001).
Conclusion: Our findings suggested that COVID-19 patients with the moderate type of disease receiving CCP units with high antibody titers in the early stages of the disease experienced greater effectiveness of CCP therapy.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: